Here, we aimed to determine whether inducing the overexpression of human αsyn or tau in well-characterized, transgenic AD and PD mice models would exacerbate the existing phenotype and recapitulate the neurobiology of LBD. The gene discussed is MAPT; the disease is Alzheimer disease.